



Recordati Rare Diseases UK Limited Modern Slavery Act Statement 2023

This statement has been published in accordance with the Modern Slavery Act 2015. The Act requires businesses to state the actions they have taken during the financial year to ensure that modern slavery is not taking place in their operations and supply chains.

The aim of this statement is to provide an update on the progress that Recordati Rare Diseases UK Limited ("Recordati") has made during the financial year ending 31 December 2023, and will continue to make, to prevent modern slavery in the business and our supply chains.

Structure and Business

Recordati based in the UK and is part of the Recordati S.p.A group ("Recordati Group"). Recordati S.p.A is one of Europe's leading pharmaceutical and healthcare companies, with headquarters in Milan.

Supply Chains

Recordati's supply chains include the manufacture and packaging of pharmaceutical products and the promotion, sale, and distribution of pharmaceutical products globally.

Recordati Group recognises the importance of protecting and promoting human rights throughout the entire supply chain and guarantees respect for fundamental human rights, renouncing the exploitation of labour, and is committed to ensure that our suppliers do the same. To this purpose, we ask our partners (including suppliers) to comply with the ethical and behavioural standards given in our Code. This obligation is formalised through dedicated contractual clauses.

Actions taken

Recordati has:

- Adopted the Recordati Group's Code of Ethics which ensures the highest standards of ethics.
- Implemented an ethics hotline to facilitate the reporting of any code of conduct concerns our employees or third parties may have.

Future plans

Recordati plans to:

- Identify high risk suppliers (such as pre-wholesalers and manufacturers) and plans to conduct further in-depth due diligence on such suppliers with a focus on anti-modern slavery and human trafficking.



- Ask anti-modern slavery compliance questions in our due diligence questionnaire used for new third parties we engage with.
- Update our partner distribution contract templates to include clauses around anti-modern slavery and human trafficking in high-risk jurisdictions.

This Statement has been approved by Recordati Rare Diseases UK Limited as of 13th May 2024

DocuSigned by:

Luigi Longinotti

BF43A2555A27472...

Name: Luigi Longinotti

Title: DIRECTOR

Date: 13-May-2024